Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design. - Test2 - elhamkhani - TriplyDB

Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.

Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.

http://www.wikidata.org/entity/Q38461481

about

Drugs for the acute treatment of migraine in children and adolescents Biomarker-Guided Adaptive Trial Designs in Phase II and Phase III: A Methodological Review Medication overuse in children and adolescents Advances in pediatric pharmacology, therapeutics, and toxicology.Diagnosis and Treatment of Childhood Migraine.Is migraine a risk factor for pediatric stroke?Adaptive trial designs: a review of barriers and opportunities Predictors of Triptan Response in Pediatric Migraine Overview, hurdles, and future work in adaptive designs: perspectives from a National Institutes of Health-funded workshop.Pharmacological treatment of acute migraine in adolescents and children.The efficacy of triptans in childhood and adolescence migraine.Pediatric migraine: abortive management in the emergency department.Oral triptans in children and adolescents: an update.Population Pharmacokinetic Analysis of Zolmitriptan and Its Metabolite in Adults and Adolescents to Support Dose Selection in Children With Migraine.Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review.Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine.Triptans and migraine: advances in use, administration, formulation, and development.Efficacy and tolerability of zolmitriptan nasal spray for the treatment of acute migraine in adolescents: Results of a randomized, double-blind, multi-center, parallel-group study (TEENZ).Adaptive designs in clinical trials: why use them, and how to run and report them.Long-Term Open-Label Safety Study of Rizatriptan Acute Treatment in Pediatric Migraineurs

P2860

Q24185885-8BEB9EE6-EBFB-40B4-A75E-084034D51A33 Q26766584-43E7F706-E333-4D7B-9937-E91E8F8D05BC Q27006583-C3E90FD5-060B-4B1E-9AE2-1813DA317131 Q33998667-0EAFB905-D524-48E8-91BB-8176B5F3BBAA Q34541963-688D4DE1-6FAF-4F52-BFB8-D0C0914846EB Q36042589-0222B9F2-1E7A-42ED-9E96-FF3F1BA3AA5D Q36460054-9D2D695B-D434-42C8-A135-E6800819B0EF Q36984540-5BB263A5-A1D7-4F58-8251-2EDCEA35D7CD Q38068392-BA414396-5398-4ABA-973C-191235CB1624 Q38098096-B1B57DFD-7027-48A2-9BB9-95EEDCDFD2E2 Q38109574-F8F48A68-6640-4A4C-85D4-D334AFC871F4 Q38186801-620B83F2-321C-4642-98E2-D5213179C60B Q38371235-AA1091E1-01A6-43F9-B0B3-0B1D02DC2311 Q38674724-1EE5E98E-F104-4D16-945D-5D5C7617A35B Q38704466-EE3FE6F0-457B-4ED9-8535-FF0234473ABB Q38922344-8888E1CA-F20D-430B-8D7F-87B58C881E3C Q38994955-0AF65F85-EEA5-4764-AB18-6A89F0CAD122 Q39666067-D102A3DE-D8C2-4CE9-90B3-2C4A31C59C26 Q52681001-41DD8C70-4A29-49B3-8B3F-692D89AE912B Q57197699-C12A56D3-A67B-4F56-A042-B933EFEDEB90

P2860

Efficacy and tolerability of rizatriptan in pediatric migraineurs: results from a randomized, double-blind, placebo-controlled trial using a novel adaptive enrichment design.

http://www.wikidata.org/entity/Q38461481

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Efficacy and tolerability of r ...... el adaptive enrichment design.

@en

type

label

Efficacy and tolerability of r ...... el adaptive enrichment design.

@en

prefLabel

Efficacy and tolerability of r ...... el adaptive enrichment design.

@en

P1433

Q38461481-FF315F94-6497-4311-B0EF-35C69082A1AD

P1476

Q38461481-9C09944C-E734-4520-AAE9-74F6860441E3

P2093

Q38461481-06AC1C54-F42D-46EA-9BB9-04624CE1F577

Q38461481-082EF337-EFE9-45B6-8E00-EEB20771DB52

Q38461481-385A7A9F-3751-496C-BB18-A5274CCF11AA

Q38461481-4D99D55C-5E05-4741-8302-733DA72478A9

Q38461481-54164968-ABAE-4159-BEE9-BDE4D0157195

Q38461481-5B1CD83E-2F53-44E7-8720-D2FDCB7E7F8B

Q38461481-61EB6C71-B980-444C-B199-D1767B64A2AA

Q38461481-79CFE641-4415-4507-B474-3706B2D47EA4

Q38461481-9623E4D3-C70F-40FC-860B-5E555A12A8F9

Q38461481-AAC140F5-4E74-4F08-BE33-28EA04267C27

P2860

Q38461481-143A8603-BEFD-4972-B963-84ACA6B7E784

Q38461481-2DC429E2-5318-4CFA-BC92-3E65BD77CC10

Q38461481-31C1188A-D973-4083-A222-31AB5943E7AE

Q38461481-32924D48-31A7-491A-BE75-359796DD00C3

Q38461481-32BA5D3C-E884-4059-A871-04E979EF4F88

Q38461481-41B11B90-1D8D-4CE2-B65C-DBC0FEE1B4FB

Q38461481-659979E2-D156-41D9-A1DB-A23D28F11E6E

Q38461481-67325240-D4EE-4D37-B4C1-1757891B9136

Q38461481-90077EC2-5037-4657-8C77-501F977B0533

Q38461481-9FEBACF4-F485-479C-8E36-9623469B2E29

P304

Q38461481-8C8DEF05-1B35-42A3-879B-DDCF33243F62

P31

Q38461481-64F4AF0E-ACA4-46C4-86D3-1109F06F17DA

P356

Q38461481-9863F72C-0016-40F9-A283-F51442FA201A

P407

Q38461481-06760548-63BC-4524-9991-216ED25480A2

P433

Q38461481-3BD9640F-8310-40E4-A974-DCA0BB15B912

P478

Q38461481-65D8135B-FBCF-4C03-BEE4-0E1B6E0C0CC9

P50

Q38461481-4CA1B3D0-5830-4684-9651-57CAC5740C26

P577

Q38461481-013D7C9F-B56C-4EFB-ADE9-74A707CFD48E

P5875

Q38461481-0A0588D2-26A6-416E-ACF0-F4AEB85D7409

P698

Q38461481-27783DD7-8165-442F-9770-F18CD32E1B96

P921

Q38461481-37680631-45C4-402A-A21E-2C274AB7A829

P356

0333102412451358

P1433

P1476

Efficacy and tolerability of r ...... el adaptive enrichment design.

@en

P2093

Christopher Assaid

http://www.w3.org/2001/XMLSchema#string

Christopher Lines

http://www.w3.org/2001/XMLSchema#string

David J Hewitt

http://www.w3.org/2001/XMLSchema#string

David Michelson

http://www.w3.org/2001/XMLSchema#string

Donald Lewis

http://www.w3.org/2001/XMLSchema#string

Eric Pearlman

http://www.w3.org/2001/XMLSchema#string

Erin Mahoney

http://www.w3.org/2001/XMLSchema#string

Kathryn Connor

http://www.w3.org/2001/XMLSchema#string

Lyn Harper Mozley

http://www.w3.org/2001/XMLSchema#string

Mirja Hämäläinen

http://www.w3.org/2001/XMLSchema#string

P2860

Practice parameter: pharmacological treatment of migraine headache in children and adolescents: report of the American Academy of Neurology Quality Standards Subcommittee and the Practice Committee of the Child Neurology Society.

A randomized trial of rizatriptan in migraine attacks in children.

The placebo responder rate in children and adolescents.

The placebo response in studies of acute migraine.

Prevalence of headache and migraine in children and adolescents: a systematic review of population-based studies.

Placebo efficacy in childhood and adolescence migraine: an analysis of double-blind and placebo-controlled studies.

Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial.

Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study.

Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies.

Children's ibuprofen suspension for the acute treatment of pediatric migraine.

P304

750-765

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/0333102412451358

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

32

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-06-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

227343762

http://www.w3.org/2001/XMLSchema#string

P698

22711898

http://www.w3.org/2001/XMLSchema#string

P921